A new Chinese COVID-19 vaccine, developed by Chongqing Zhifei company, showed efficiency by 78% against the Delta variant, Al Ain reported on Saturday.
Moreover, the Bloomberg website highlighted that the final stage of the new vaccine’s clinical trials proved that the vaccine is effective by 92.93 against Alfia, and 81% against severe COVID-19 infections.
In the same context, the vaccine’s manufacturing company revealed that no medical complications or deaths were recorded among persons who received the vaccine.
Bloomberg cited the giant Pharmaceutical company, saying China approved the newly-manufactured vaccine for emergency use to be given to children aged between 13, and 17 years old.
In June, China took the earliest steps for giving vaccines to children after successfully vaccinated 80% of the country’s population. It started by approving the Sinovac vaccine for children aged from 3 to 17 to protect them against any mutated versions of the virus amid the outbreak of Delta variant worldwide.
Early this month, the National Committee for Health said that the mainland has reported 96 new infections with the Coronavirus today, Wednesday, compared with 90 cases on Tuesday. The committee explained that 71 of the infected people were locals.
It is worth noting that 27 cases were clear of the known symptoms of COVID-19 in spite of their infection with the deadly virus.
About 93 thousand infections were registered in the country since the outbreak of the disease later in 2019, meanwhile, the death toll is still at 4636 cases without any change so far.